Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €4.80 EUR
Change Today -0.359 / -6.96%
Volume 493.0
As of 7:24 AM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

thrombogenics nv (TG4) Snapshot

Open
€5.05
Previous Close
€5.16
Day High
€5.05
Day Low
€4.80
52 Week High
04/25/14 - €24.18
52 Week Low
04/1/15 - €4.80
Market Cap
173.3M
Average Volume 10 Days
476.0
EPS TTM
--
Shares Outstanding
36.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for THROMBOGENICS NV (TG4)

Related News

No related news articles were found.

thrombogenics nv (TG4) Related Businessweek News

No Related Businessweek News Found

thrombogenics nv (TG4) Details

ThromboGenics NV, an integrated biopharmaceutical company, is engaged in developing and commercializing ophthalmic and oncology medicines in Belgium and interntionally. The company offers JETREA for the treatment of symptomatic vitreomacular traction. It has a collaboration agreement with BioInvent International AB to develop anti-factor VIII, an anti-coagulation treatment for various indications, such as the prevention and treatment of deep vein thrombosis, and the treatment of atrial fibrillation; and anti-placental growth factor, an anti-angiogenic component for the treatment of various disorders, including cancer, age-related macula degeneration, retinopathy, and inflammation. The company also has a research and license agreement with Bharat Biotech; a production agreement with Fujifilm Diosynth Biotechnologies UK Limited; a license agreement Grifols and NuVue Technologies, Inc.; a life sciences research partnership with VZW; agreements with Eleven Biotherapeutics, Bicycle Therapeutics, and Flanders Institute for Biotechnology; and cooperation agreements with Centrum voor Moleculaire en Vasculaire Biologie and KULeuven. ThromboGenics NV was founded in 1991 and is headquartered in Leuven, Belgium.

Founded in 1991

thrombogenics nv (TG4) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: €448.0K
Compensation as of Fiscal Year 2013.

thrombogenics nv (TG4) Key Developments

ThromboGenics NV Announces Positive Topline Results from OASIS Study

ThromboGenics NV announced positive topline results from its OASIS study with JETREA(R) (ocriplasmin). The OASIS study is a randomized, sham controlled, double masked study that followed up patients for 24 months post injection. The study was designed to provide long term controlled efficacy and safety data for JETREA(R) in patients being treated for symptomatic vitreomacular adhesion (sVMA). The OASIS study is the first controlled study with JETREA(R) of its kind since the results of the pivotal Phase III program were announced in 2011. The study includes 24 month follow up data, the period patients have been studied post treatment with this novel medicine. The key findings of the study were 41.7% of patients treated with JETREA(R) achieved VMA resolution at Day 28 post injection compared with only 6.2% of patients who received a sham injection (p<0.001); and the JETREA(R) safety profile in this 24 month follow up study was consistent with the drug's overall safety profile as known from the approved label. No new safety events were identified. The OASIS data compare favorably with the results from the pivotal Phase III program with JETREA(R) where VMA resolution was seen in 26.5% of patients at Day 28 post injection. In the Phase III program 10.1% of patients treated with a placebo injection achieved VMA resolution (p<0.001). The OASIS data show the importance of improved patient selection in generating higher rates of VMA resolution with JETREA(R). Recent real world data have confirmed that access to more advanced diagnostic technology such as SD-OCT, has enabled retina physicians to improve patient selection. As a result they have been able to select patients with focal VMA and an absence of Epiretinal Membrane (ERM), two criteria which have been shown to lead to better treatment outcomes with JETREA(R).

ThromboGenics NV Reports Consolidated Earnings Results for the Year December 31, 2014

ThromboGenics NV reported consolidated earnings results for the year December 31, 2014. For the year, the group reported sales of €13.8 million compared to €112.8 million, operating loss of €52.7 million compared to operating results of €25.5 million, loss before income tax of €51.0 million compared to result before income tax of €26.4 million, loss attributable equity holders of the company of €51.1 million or €1.42 per basic and diluted share compared to profit attributable equity holders of the company of €26.4 million or €0.71 per diluted share, net used in operating activities of €46.6 million compared to net from operating activities of €25.7 million, acquisition of intangible assets of €12,000 compared to €3.4 million and acquisition of property, plant and equipment of €0.6 million compared to €2.2 million for the last year.

ThromboGenics NV, 2014 Earnings Call, Mar 12, 2015

ThromboGenics NV, 2014 Earnings Call, Mar 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TG4:GR €4.80 EUR -0.359

TG4 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TG4.
View Industry Companies
 

Industry Analysis

TG4

Industry Average

Valuation TG4 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.4x
Price/Book 0.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THROMBOGENICS NV, please visit www.thrombogenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.